Nebulized nintedanib (AP02) for idiopathic pulmonary fibrosis demonstrates favorable safety and lung lining fluid exposures: results from two phase I safety, tolerability, and pharmacokinetics studies
Michelle Palacios, Rebecca Boone, Stephen Pham, Sam Francis, Jason Lickliter, Mark Surber, Deepthi Nair, Felix A Woodhead, Howard M Lazarus, Craig S Conoscenti & Melissa Rhodes
